Clinicopathological, prognostic and predictive value of CD166 expression in colorectal cancer: a meta-analysis.
Clinicopathological, prognostic and predictive value of CD166 expression in colorectal cancer: a meta-analysis.
复制标题
CD166 表达在结直肠癌中的临床病理学、预后和预测价值：一项荟萃分析
DOI：
10.18632/oncotarget.17442
复制
发表时间：
2017-09-08
期刊：
影响因子：
--
通讯作者：
Hou F
中科院分区：
文献类型：
--
作者：
Han S;Yang W;Zong S;Li H;Liu S;Li W;Shi Q;Hou F
CD 166已被鉴定为结直肠癌（CRC）中重要的癌症干细胞（CSC）标志物。本研究的目的是探讨CD 166表达与临床特征之间的关系，并研究CD 166表达对CRC患者生存的作用。本荟萃分析共识别出15项研究，3,332例病例。合并OR值显示，CD 166在结直肠癌中的表达显著高于结肠腺瘤和正常结肠黏膜（OR值分别为3.48，P = 0.002和55.13，P = 0.017）。CD 166表达与肿瘤血管浸润呈负相关（OR = 0.75，P = 0.017），与性别、肿瘤部位、淋巴结状态、远处转移、临床分期、T分期及肿瘤分化程度无关。多因素回归分析显示，CD 166表达与总生存期（OS）的预后无关（HR = 1.20，95% CI = 0.45-3.22，P = 0.72）。一项研究报道，使用多变量逻辑回归分析，CD 166表达可能是II期CRC患者生存的预测因子（OS：OR = 9.97，P = 0.035;疾病特异性生存：OR = 29.02，P = 0.011）。我们的研究结果表明，CD 166表达可能与CRC致癌作用和血管侵袭风险降低相关，并且它可能成为II期CRC患者生存的预测生物标志物，但大样本量的额外研究对于验证预后和预测至关重要CD 166表达的价值。
CD166 has been identified as an important cancer stem cell (CSC) marker in colorectal cancer (CRC). The purpose of our study was to investigate the relationship between CD166 expression and clinical features and to examine the role of CD166 expression on the survival of patients with CRC. A total of 15 studies with 3,332 cases were identified in this meta-analysis. The pooled OR indicated that CD166 expression was significantly higher in CRC than in colonic adenomas or normal colonic mucosa (OR = 3.48, P = 0.002 and OR = 55.13, P = 0.017, respectively). CD166 expression was found to be negatively correlated with vascular invasion (OR = 0.75, P = 0.017), but it was not associated with gender, tumor location, lymph node status, distant metastasis, clinical stage, T classification or tumor differentiation. Meanwhile, CD166 expression was not associated with the prognosis of overall survival (OS) (HR = 1.20, 95% CI = 0.45-3.22, P = 0.72) in multivariate regression analysis. One study reported that CD166 expression may be a predictor of survival in stage II CRC patients using multivariate logistic regression analysis (OS: OR = 9.97, P = 0.035; disease-specific survival: OR = 29.02, P = 0.011). Our findings suggest that CD166 expression may be correlated with CRC carcinogenesis and a decreased risk of vascular invasion, and it may become a predictive biomarker of survival for stage II CRC patients, but additional studies with large sample sizes are essential to validate the prognostic and predictive values of CD166 expression.
登录
查看更多内容
影响因子：
8.8
作者：
通讯作者：
--
影响因子：
2.6
作者：
Donizy, Piotr;Zietek, Marcin;Matkowski, Rafal
通讯作者：
Matkowski, Rafal
DOI：
10.1097/pai.0000000000000140
发表时间：
2015-11-01
影响因子：
1.6
作者：
Eom, Dae-Woon;Hong, Seung-Mo;Yu, Eunsil
通讯作者：
Yu, Eunsil
影响因子：
8.8
作者：
Amankwatia, E. B.;Chakravarty, P.;Carey, F. A.;Weidlich, S.;Steele, R. J. C.;Munro, A. J.;Wolf, C. R.;Smith, G.
通讯作者：
Smith, G.
影响因子：
3.4
作者：
Piscuoglio, Salvatore;Lehmann, Frank S.;Terracciano, Luigi M.
通讯作者：
Terracciano, Luigi M.